Asymchem Laboratories (Tianjin) Co., Ltd., a contract development and manufacturing organization (CDMO) serving the global pharmaceutical and biotech industry, has completed construction of a new building at its Dunhua, China, production site. The expansion will add nearly 500 cubic meters of batch capacity to meet demands for upcoming commercialization projects. In addition, an active pharmaceutical ingredient (API) building expansion was completed at the company’s Tianjin site, with an expected new batch capacity of 160 cubic meters.

“To meet the rapidly growing demand of Asymchem’s clients and projects, we have accelerated the construction of several small molecule R&D and production sites across China,” said Chen Chaoyong, executive vice president of manufacturing, Asymchem. “By the end of 2022, we plan to have added 1,700 cubic meters of small molecule batch capacity in Dunhua, Tianjin and Yangtze River Delta, doubling existing batch capacity.”

Additionally, Asymchem plans to continue to increase the application of continuous flow technology in all of its sites. This includes upgrading several current modules and buildings and adding continuous flow equipment in new facilities.

Dr. James Gage, chief scientific officer, Asymchem, said, “With the completion of additional production sites, large-scale application of continuous flow technology, optimized capacity utilization, and consistent blockbuster commercial orders, we have sufficient space to undertake new customers and projects well into 2022 and beyond.”